The 6 most recent market catalysts affecting $SPRY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 85
Reported Sunday, Spyre Shows Anti-α4β7, Anti-TL1A And Anti-IL-23 Antibodies Each Efficacious In Humanized Mouse Colitis Model, With Combinations Further Improving Efficacy, At UEGW 2026
This news is a major positive catalyst for Spyre Therapeutics (SPRY) as it validates their drug discovery platform and the potential of their anti-α4β7, anti-TL1A, and anti-IL-23 a…
Oct 6, 2026
Corporate Catalyst
Bearish
Impact 85
Spyre Therapeutics shares are trading lower after the company announced the pricing of its $350 million offering of 4,117,648 shares at $85.00 per share.
The pricing of a $350 million stock offering at $85.00 per share, especially if below the recent trading price, typically leads to a negative market reaction for the issuing compan…
Oct 6, 2026
Corporate Catalyst
Neutral
Impact 85
Reported Earlier, Spyre Therapeutics Prices $350M Public Offering Of 4,117,648 Common Shares At $85.00 Per Share, Plans To Fund Gastroenterology, Rheumatology And Dermatology Programs
This public offering is a significant corporate catalyst for Spyre Therapeutics. While the issuance of new shares at $85.00 will dilute existing shareholders, the substantial capit…
Oct 5, 2026
Corporate Catalyst
Neutral
Impact 75
Spyre Therapeutics Announces Proposed Public Offering; Size Not Disclosed
This headline represents a significant corporate catalyst for Spyre Therapeutics. A public offering, especially with an undisclosed size, typically leads to short-term downward pre…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 75
ARS Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results.
The mixed Q2 financial results for ARS Pharmaceuticals (SPRY) are a direct corporate catalyst, leading to a negative market reaction. Investors are likely weighing the positive asp…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate
ARS Pharmaceuticals (SPRY) announced Q2 earnings that showed a substantial miss on EPS expectations, reporting $(0.63) against an estimated $(0.48). This 31.25% miss, coupled with …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.